5 citations
,
December 2024 in “Anais Brasileiros de Dermatologia” This study outlines treatment options for alopecia, suggesting intralesional corticosteroids for localized adult cases and Janus Kinase inhibitors for severe cases, emphasizing a balance between hair regrowth rate and managing side effects.
March 2026 in “British Journal of Dermatology” This study found that the TYK2 inhibitor deucravacitinib did not significantly improve hair regrowth in patients with alopecia areata compared to placebo, suggesting it may not be effective for this condition. No new safety issues were identified.
July 2026 in “Hippocratic Journal of Unani Medicine” In this case study, a 34-year-old male with alopecia areata was treated successfully using Unani medicine, including cupping therapy, over three months, but the authors indicated the need for further research to confirm the safety and efficacy of these treatments.
November 2023 in “Research Square (Research Square)” This double-blinded randomized clinical trial found that combining topical vitamin D analog (calcipotriol) and intra-lesion PRP led to a greater reduction in hair loss severity in alopecia areata patients compared to either treatment alone, with significant improvements observed across all groups.
44 citations
,
November 2016 in “Journal of The American Academy of Dermatology” This article updates a diagnostic tool (SALT II) for assessing hair loss by adding more precise measurements of scalp surface area, particularly useful for various types of alopecia.
